Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis

INTRODUCTION: Enzalutamide, apalutamide, and darolutamide have all been approved by Food and Drug Administration to treat high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) since 2018 based on interim results of several phase III clinical trials. Final analyses of long-term overa...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulati, Yelin, Fan, Yu, Yu, Wei, Zhang, Qian, He, Zhisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555656/
https://www.ncbi.nlm.nih.gov/pubmed/34722276
http://dx.doi.org/10.3389/fonc.2021.733202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555656/
https://www.ncbi.nlm.nih.gov/pubmed/34722276
http://dx.doi.org/10.3389/fonc.2021.733202

Ejemplares similares